PL2739153T3 - Leczenie raka sutka - Google Patents

Leczenie raka sutka

Info

Publication number: PL2739153T3
Authority: PL; Poland
Prior art keywords: nutc; cancer; treatment; nutc cancer
Prior art date: 2011-07-29

Application number

PL12846720T

Other languages

English (en)

Inventor

Andrew A. Protter

Jennifer Richer

Dawn Cochrane

Original Assignee

Medivation Prostate Therapeutics Llc

Univ Colorado Regents

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-07-29

Filing date

2012-07-27

Publication date

2019-04-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48192564&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2739153(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-07-27 Application filed by Medivation Prostate Therapeutics Llc, Univ Colorado Regents filed Critical Medivation Prostate Therapeutics Llc

2019-04-30 Publication of PL2739153T3 publication Critical patent/PL2739153T3/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL12846720T 2011-07-29 2012-07-27 Leczenie raka sutka PL2739153T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201161513361P	2011-07-29	2011-07-29
EP12846720.6A EP2739153B1 (en)	2011-07-29	2012-07-27	Treatment of breast cancer
PCT/US2012/048471 WO2013066440A1 (en)	2011-07-29	2012-07-27	Treatment of breast cancer

Publications (1)

Publication Number	Publication Date
PL2739153T3 true PL2739153T3 (pl)	2019-04-30

Family

ID=48192564

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL12846720T PL2739153T3 (pl)	2011-07-29	2012-07-27	Leczenie raka sutka

Country Status (18)

Country	Link
US (4)	US9517229B2 (pl)
EP (4)	EP2739153B1 (pl)
JP (2)	JP6158180B2 (pl)
KR (1)	KR101923250B1 (pl)
CN (1)	CN103997894B (pl)
BR (1)	BR112014002200A2 (pl)
CA (1)	CA2843417C (pl)
CY (1)	CY1121038T1 (pl)
DK (1)	DK2739153T3 (pl)
EA (1)	EA028452B1 (pl)
ES (1)	ES2696074T3 (pl)
HU (1)	HUE040524T2 (pl)
MX (1)	MX359664B (pl)
PH (1)	PH12014500248B1 (pl)
PL (1)	PL2739153T3 (pl)
PT (1)	PT2739153T (pl)
SI (1)	SI2739153T1 (pl)
WO (1)	WO2013066440A1 (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2696074T3 (es) *	2011-07-29	2019-01-14	Medivation Prostate Therapeutics Llc	Tratamiento del cáncer de mama
GB201216017D0 (en)	2012-09-07	2012-10-24	Cancer Rec Tech Ltd	Inhibitor compounds
ES2836424T3 (es)	2012-09-26	2021-06-25	Aragon Pharmaceuticals Inc	Antiandrógenos para tratar el cáncer de próstata no metastásico y resistente a la castración
JOP20200097A1 (ar)	2013-01-15	2017-06-16	Aragon Pharmaceuticals Inc	معدل مستقبل أندروجين واستخداماته
SG11201508302PA (en)	2013-04-17	2015-11-27	Signal Pharm Llc	Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
KR20160070188A (ko) *	2013-11-07	2016-06-17	데시페라 파마슈티칼스, 엘엘씨.	암치료에 유용한 tie2 키나아제의 억제 방법
JP6945587B2 (ja) *	2013-11-07	2021-10-06	デシフェラファーマシューティカルズ，エルエルシー	ガンの処置に有用なｔｉｅ２キナーゼの阻害方法
WO2015184145A1 (en) *	2014-05-28	2015-12-03	Eisai R&D Management Co., Ltd.	Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer
AU2015360767A1 (en)	2014-12-12	2017-06-08	Medivation Prostate Therapeutics Llc	Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer
CN107530291A (zh)	2015-03-03	2018-01-02	奎尔波特股份有限公司	双重负载的脂质体药物制剂
WO2016141167A1 (en)	2015-03-03	2016-09-09	Cureport, Inc.	Combination liposomal pharmaceutical formulations
CN104857517B (zh) *	2015-05-14	2018-04-27	南京海纳医药科技股份有限公司	一种恩杂鲁胺软胶囊及其制备方法
US9963433B2 (en) *	2016-01-29	2018-05-08	Wayne State University	Anticancer drugs including the chemical structures of an androgen receptor ligand and a histone deacetylase inhibitor
JP7282045B2 (ja)	2017-06-22	2023-05-26	セルジーンコーポレイション	Ｂ型肝炎ウイルス感染を特徴とする肝細胞癌の治療
US10702508B2 (en)	2017-10-16	2020-07-07	Aragon Pharmaceuticals, Inc.	Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
CN107987055A (zh) *	2017-12-19	2018-05-04	刘秀云	硫代咪唑二酮类雄激素受体拮抗剂及其用途
SG11202007198WA (en)	2018-01-31	2020-08-28	Deciphera Pharmaceuticals Llc	Combination therapy for the treatment of gastrointestinal stromal tumors
JP7523351B2 (ja)	2018-01-31	2024-07-26	デシフェラ・ファーマシューティカルズ，エルエルシー	肥満細胞症の治療のための併用療法
WO2020113094A1 (en)	2018-11-30	2020-06-04	Nuvation Bio Inc.	Pyrrole and pyrazole compounds and methods of use thereof
US11292782B2 (en)	2018-11-30	2022-04-05	Nuvation Bio Inc.	Diarylhydantoin compounds and methods of use thereof
TWI878335B (zh)	2019-08-12	2025-04-01	美商迪賽孚爾製藥有限公司	治療胃腸道基質瘤方法
EP4013412A1 (en)	2019-08-12	2022-06-22	Deciphera Pharmaceuticals, LLC	Ripretinib for treating gastrointestinal stromal tumors
IL293866A (en)	2019-12-30	2022-08-01	Deciphera Pharmaceuticals Llc	Compositions of amorphous kinase inhibitors and methods of using them
LT4084779T (lt)	2019-12-30	2024-11-11	Deciphera Pharmaceuticals, Llc	1-(4-brom-5-(1-etil-7-(metilamino)-2-okso-1,2-dihidro-1,6-naftiridin-3-il) -2- fluorfenil)-3-fenilkarbamido kompozicijos
CA3188358A1 (en) *	2020-08-03	2022-02-10	Robert Scott SEITZ	Classifying tumors and predicting responsiveness
US11779572B1 (en)	2022-09-02	2023-10-10	Deciphera Pharmaceuticals, Llc	Methods of treating gastrointestinal stromal tumors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4559157A (en)	1983-04-21	1985-12-17	Creative Products Resource Associates, Ltd.	Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr)	1983-08-30	1985-04-24	Oreal	Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en)	1987-06-23	1989-04-11	Neutrogena Corporation	Skin protective composition
US4992478A (en)	1988-04-04	1991-02-12	Warner-Lambert Company	Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en)	1988-09-12	1990-07-03	University Of New York	Treatment of damaged bone marrow and dosage units therefor
US7709517B2 (en)	2005-05-13	2010-05-04	The Regents Of The University Of California	Diarylhydantoin compounds
RS53967B1 (sr)	2005-05-13	2015-08-31	The Regents Of The University Of California	Diaril hidantoin jedinjenja kao antagonisti receptora androgena za lečenje raka
WO2007061876A2 (en)	2005-11-23	2007-05-31	University Of Utah Research Foundation	Methods and compositions involving intrinsic genes
DK3100727T3 (en) *	2006-03-27	2018-11-12	Univ California	Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
US8110594B2 (en)	2006-03-29	2012-02-07	The Regents Of The University Of California	Diarylthiohydantoin compounds
PE20091262A1 (es)	2007-10-26	2009-09-09	Univ California	Compuestos de diarilhidantoina como antagonistas del receptor de androgeno
US8450290B2 (en) *	2007-11-26	2013-05-28	Enzon Pharmaceuticals, Inc.	Methods for treating androgen receptor dependent disorders including cancers
US20110130296A1 (en)	2008-03-14	2011-06-02	The Regents Of The University Of California	Multi-gene classifiers and prognostic indicators for cancers
US9631239B2 (en)	2008-05-30	2017-04-25	University Of Utah Research Foundation	Method of classifying a breast cancer instrinsic subtype
KR20110130439A (ko) *	2009-02-24	2011-12-05	메디베이션 프로스테이트 테라퓨틱스 인코퍼레이티드	특정 디아릴히단토인 및 디아릴티오히단토인 화합물
US8710086B2 (en) *	2009-04-09	2014-04-29	Medivation Technologies, Inc.	Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods of use thereof
US8507195B2 (en)	2009-08-20	2013-08-13	The Regents Of The University Of Colorado	MiRNAs dysregulated in triple-negative breast cancer
WO2011044327A1 (en)	2009-10-07	2011-04-14	Medivation Prostate Therapeutics, Inc.	Substituted phenylcarbamoyl alkylamino arene compounds and n,n'-bis-arylurea compounds
CA2830240A1 (en)	2011-03-15	2012-09-20	The University Of North Carolina At Chapell Hill	Methods of treating breast cancer with anthracycline therapy
ES2696074T3 (es) *	2011-07-29	2019-01-14	Medivation Prostate Therapeutics Llc	Tratamiento del cáncer de mama
CA2857505A1 (en)	2011-11-30	2013-06-06	The University Of North Carolina At Chapel Hill	Methods of treating breast cancer with taxane therapy
EP2888594B1 (en)	2012-08-23	2018-08-15	The Regents of the University of Colorado, a body corporate	Method for determining breast cancer treatment
US9175291B2 (en)	2012-10-11	2015-11-03	Isis Pharmaceuticals Inc.	Modulation of androgen receptor expression
US20140154681A1 (en)	2012-11-12	2014-06-05	Nanostring Technologies, Inc.	Methods to Predict Breast Cancer Outcome
US10679730B2 (en)	2013-05-28	2020-06-09	The University Of Chicago	Prognostic and predictive breast cancer signature
AU2015360767A1 (en)	2014-12-12	2017-06-08	Medivation Prostate Therapeutics Llc	Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer

2012
- 2012-07-27 ES ES12846720T patent/ES2696074T3/es active Active
- 2012-07-27 HU HUE12846720A patent/HUE040524T2/hu unknown
- 2012-07-27 PH PH1/2014/500248A patent/PH12014500248B1/en unknown
- 2012-07-27 MX MX2014001218A patent/MX359664B/es active IP Right Grant
- 2012-07-27 EP EP12846720.6A patent/EP2739153B1/en active Active
- 2012-07-27 DK DK12846720.6T patent/DK2739153T3/en active
- 2012-07-27 CA CA2843417A patent/CA2843417C/en active Active
- 2012-07-27 SI SI201231453T patent/SI2739153T1/sl unknown
- 2012-07-27 EP EP18190012.7A patent/EP3430907A1/en not_active Withdrawn
- 2012-07-27 WO PCT/US2012/048471 patent/WO2013066440A1/en not_active Ceased
- 2012-07-27 PT PT12846720T patent/PT2739153T/pt unknown
- 2012-07-27 EP EP19187649.9A patent/EP3610731A1/en not_active Withdrawn
- 2012-07-27 KR KR1020147005617A patent/KR101923250B1/ko active Active
- 2012-07-27 JP JP2014523048A patent/JP6158180B2/ja active Active
- 2012-07-27 EP EP20191500.6A patent/EP3791724A1/en not_active Withdrawn
- 2012-07-27 EA EA201400178A patent/EA028452B1/ru not_active IP Right Cessation
- 2012-07-27 CN CN201280048192.2A patent/CN103997894B/zh active Active
- 2012-07-27 BR BR112014002200A patent/BR112014002200A2/pt not_active Application Discontinuation
- 2012-07-27 PL PL12846720T patent/PL2739153T3/pl unknown
- 2012-07-27 US US14/236,036 patent/US9517229B2/en active Active
2016
- 2016-12-09 US US15/373,914 patent/US10111861B2/en active Active
2017
- 2017-03-31 JP JP2017072819A patent/JP2017141269A/ja active Pending
2018
- 2018-10-24 US US16/168,896 patent/US20190262315A1/en not_active Abandoned
- 2018-11-08 CY CY181101174T patent/CY1121038T1/el unknown
2020
- 2020-01-22 US US16/749,133 patent/US20210069154A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CN103997894A (zh)	2014-08-20
JP2014524934A (ja)	2014-09-25
EP3430907A1 (en)	2019-01-23
PH12014500248B1 (en)	2018-08-31
KR20140107174A (ko)	2014-09-04
EP3610731A1 (en)	2020-02-19
CY1121038T1 (el)	2019-12-11
EP2739153B1 (en)	2018-08-22
HK1201413A1 (en)	2015-09-04
WO2013066440A1 (en)	2013-05-10
CA2843417C (en)	2018-08-21
HUE040524T2 (hu)	2019-03-28
EP2739153A4 (en)	2015-03-11
EA028452B1 (ru)	2017-11-30
SI2739153T1 (sl)	2018-12-31
WO2013066440A9 (en)	2013-07-18
EP3791724A1 (en)	2021-03-17
MX359664B (es)	2018-10-05
DK2739153T3 (en)	2018-12-03
US20210069154A1 (en)	2021-03-11
CN103997894B (zh)	2016-08-24
US20140296312A1 (en)	2014-10-02
PH12014500248A1 (en)	2014-03-17
PT2739153T (pt)	2018-11-28
US20190262315A1 (en)	2019-08-29
JP6158180B2 (ja)	2017-07-05
EP2739153A1 (en)	2014-06-11
ES2696074T3 (es)	2019-01-14
KR101923250B1 (ko)	2018-11-28
CA2843417A1 (en)	2013-05-10
MX2014001218A (es)	2014-08-22
HK1198867A1 (en)	2015-06-19
JP2017141269A (ja)	2017-08-17
US9517229B2 (en)	2016-12-13
EA201400178A1 (ru)	2014-11-28
BR112014002200A2 (pt)	2017-03-07
US10111861B2 (en)	2018-10-30
US20170087132A1 (en)	2017-03-30

Publication	Publication Date	Title
IL272206B (en)	2022-02-01	Combination therapy for treating cancer
HUE048876T2 (hu)	2020-08-28	Rákos megbetegedések kezelése
PL2739153T3 (pl)	2019-04-30	Leczenie raka sutka
HUE046790T2 (hu)	2020-03-30	A rák kezelésének módszerei
DK2717941T3 (da)	2020-07-13	Behandling af cancer
BR112014007603A2 (pt)	2017-06-13	métodos de tratamento do câncer
HUE047198T2 (hu)	2020-04-28	Fitokannabinoidok emlõrák kezelésére
DK2785349T3 (da)	2020-01-02	Kombinationsbehandling af cancer
LT2885010T (lt)	2020-04-27	Tautopatijos gydymo būdai
PL2552438T3 (pl)	2016-12-30	Sposoby leczenia raka wątrobowokomórkowego
EP2723384A4 (en)	2015-08-12	TREATMENT OF PROTEINOPATHIES
EP2920308A4 (en)	2016-06-29	CANCER TREATMENT
HUE053247T2 (hu)	2021-06-28	Mieloszuppresszió kezelése
BR112014012880A2 (pt)	2017-06-13	tratamento imunogênico do câncer
HRP20190046T1 (hr)	2019-05-03	Kombinirana terapija za liječenje raka
IL228430A0 (en)	2013-12-31	Cancer treatment
BR112013011659A2 (pt)	2016-08-02	métodos de tratamento do câncer
EP2817011A4 (en)	2015-08-19	CANCER TREATMENT
EP2903644A4 (en)	2016-03-09	TREATMENT OF CANCER
GB201217892D0 (en)	2012-11-21	Treatment of cancer
PL2780003T3 (pl)	2020-06-29	Leczenie niedoczynności kory nadnerczy
DK2694056T3 (da)	2020-01-02	Terapeutisk behandling
EP2825198A4 (en)	2015-10-28	THERAPEUTIC AGAINST CANCER
GB201217890D0 (en)	2012-11-21	Treatment of cancer
GB201121783D0 (en)	2012-02-01	Treatment of cancer